Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2017 | Pages:
124 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Alcohol Addiction - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Pipeline Review, H1 2017, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape. Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 10, 1, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Alcohol Addiction - Overview Alcohol Addiction - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Alcohol Addiction - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Alcohol Addiction - Companies Involved in Therapeutics Development AbbVie Inc Addex Therapeutics Ltd Adial Pharmaceuticals LLC Astraea Therapeutics LLC BioCorRx Inc Bionex Pharmaceuticals LLC Bioprojet SCR Cerecor Inc Chronos Therapeutics Ltd Corcept Therapeutics Inc Curemark LLC Eli Lilly and Company Ethypharm SA Euthymics Bioscience Inc H. Lundbeck A/S Heptares Therapeutics Ltd Indivior Plc Kinnov Therapeutics SAS Kyorin Pharmaceutical Co Ltd Lohocla Research Corp Omeros Corp Pfizer Inc Savant HWP Inc SK Biopharmaceuticals Co Ltd Tonix Pharmaceuticals Holding Corp VM Discovery Inc XenoPort Inc Zynerba Pharmaceuticals Inc Alcohol Addiction - Drug Profiles (cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile Product Description Mechanism Of Action R&D Progress (disulfiram + selegiline) - Drug Profile Product Description Mechanism Of Action R&D Progress 18-MC - Drug Profile Product Description Mechanism Of Action R&D Progress A-705253 - Drug Profile Product Description Mechanism Of Action R&D Progress ABT-436 - Drug Profile Product Description Mechanism Of Action R&D Progress ADX-71441 - Drug Profile Product Description Mechanism Of Action R&D Progress amitifadine - Drug Profile Product Description Mechanism Of Action R&D Progress arbaclofen placarbil - Drug Profile Product Description Mechanism Of Action R&D Progress AT-1001 - Drug Profile Product Description Mechanism Of Action R&D Progress AT-200 - Drug Profile Product Description Mechanism Of Action R&D Progress baclofen - Drug Profile Product Description Mechanism Of Action R&D Progress carisbamate - Drug Profile Product Description Mechanism Of Action R&D Progress CERC-501 - Drug Profile Product Description Mechanism Of Action R&D Progress CM-1212 - Drug Profile Product Description Mechanism Of Action R&D Progress CTDP-002 - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress gabapentin enacarbil ER - Drug Profile Product Description Mechanism Of Action R&D Progress GET-73 - Drug Profile Product Description Mechanism Of Action R&D Progress ibudilast - Drug Profile Product Description Mechanism Of Action R&D Progress JDTic - Drug Profile Product Description Mechanism Of Action R&D Progress nalmefene - Drug Profile Product Description Mechanism Of Action R&D Progress naltrexone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress naltrexone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress naltrexone hydrochloride SR - Drug Profile Product Description Mechanism Of Action R&D Progress odelepran hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress OMS-527 - Drug Profile Product Description Mechanism Of Action R&D Progress ondansetron hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress PF-05190457 - Drug Profile Product Description Mechanism Of Action R&D Progress pitolisant - Drug Profile Product Description Mechanism Of Action R&D Progress SKL-10406 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Alcohol Addiction - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance - Drug Profile Product Description Mechanism Of Action R&D Progress VMD-2202 - Drug Profile Product Description Mechanism Of Action R&D Progress Alcohol Addiction - Dormant Projects Alcohol Addiction - Discontinued Products Alcohol Addiction - Product Development Milestones Featured News & Press Releases Jan 23, 2017: MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence Nov 28, 2016: BioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDA Sep 15, 2016: BioCorRx Announces Update From First Joint Steering Committee Meeting for Injectable Naltrexone Product Sep 03, 2016: Baclofen helps reduce the consumption of alcohol in alcohol - dependent patients Aug 31, 2016: BioCorRx Announces BioCorRx Pharmaceuticals Subsidiary; Forms Joint Steering Committee for Injectable Naltrexone Technology Jul 25, 2016: Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder Jul 20, 2016: Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health Jul 14, 2016: BioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana Jan 14, 2016: BioCorRx Announces New Agreements With Wellness Centers in Slidell, LA, Memphis and Nashville, TN, and Philadelphia, PA Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501 Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting Dec 07, 2015: BioCorRx Announces Agreements With Additional Wellness Centers in California, Wisconsin and Arizona Oct 13, 2015: Addex' ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Alcohol Addiction, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Alcohol Addiction - Pipeline by AbbVie Inc, H1 2017 Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H1 2017 Alcohol Addiction - Pipeline by Adial Pharmaceuticals LLC, H1 2017 Alcohol Addiction - Pipeline by Astraea Therapeutics LLC, H1 2017 Alcohol Addiction - Pipeline by BioCorRx Inc, H1 2017 Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2017 Alcohol Addiction - Pipeline by Bioprojet SCR, H1 2017 Alcohol Addiction - Pipeline by Cerecor Inc, H1 2017 Alcohol Addiction - Pipeline by Chronos Therapeutics Ltd, H1 2017 Alcohol Addiction - Pipeline by Corcept Therapeutics Inc, H1 2017 Alcohol Addiction - Pipeline by Curemark LLC, H1 2017 Alcohol Addiction - Pipeline by Eli Lilly and Company, H1 2017 Alcohol Addiction - Pipeline by Ethypharm SA, H1 2017 Alcohol Addiction - Pipeline by Euthymics Bioscience Inc, H1 2017 Alcohol Addiction - Pipeline by H. Lundbeck A/S, H1 2017 Alcohol Addiction - Pipeline by Heptares Therapeutics Ltd, H1 2017 Alcohol Addiction - Pipeline by Indivior Plc, H1 2017 Alcohol Addiction - Pipeline by Kinnov Therapeutics SAS, H1 2017 Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017 Alcohol Addiction - Pipeline by Lohocla Research Corp, H1 2017 Alcohol Addiction - Pipeline by Omeros Corp, H1 2017 Alcohol Addiction - Pipeline by Pfizer Inc, H1 2017 Alcohol Addiction - Pipeline by Savant HWP Inc, H1 2017 Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017 Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017 Alcohol Addiction - Pipeline by VM Discovery Inc, H1 2017 Alcohol Addiction - Pipeline by XenoPort Inc, H1 2017 Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017 Alcohol Addiction - Dormant Projects, H1 2017 Alcohol Addiction - Dormant Projects, H1 2017 (Contd..1), H1 2017 Alcohol Addiction - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
